Tuesday, September 1, 2026

Abbott Laboratories And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

January 4, 2021

Abbott Laboratories And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Nelnet, Inc.

20.4% sales growth and 6.72% return on equity

Nelnet, Inc. engages in loan servicing, communications, and education technology, services, and payment processing businesses worldwide.

Nelnet, Inc.'s sales growth this year is anticipated to be 44.5% and a negative 16.4% for next year.

Year-on-year quarterly revenue growth grew by 14.5%, now sitting on 1.1B for the twelve trailing months.

Nelnet, Inc.'s sales growth for the next quarter is 20.4%. The company's growth estimates for the ongoing quarter and the next is 406.2% and 291.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.72%.

Volatility

Nelnet, Inc.'s last day, last week, and last month's average volatility was a negative 0.96%, a negative 0.26%, and a negative 0.09%, respectively.

Nelnet, Inc.'s last day, last week, and last month's high and low average amplitude percentage was 2.40%, 1.80%, and 2.02%, respectively.

Nelnet, Inc.'s Stock Yearly Top and Bottom Value

Nelnet, Inc.'s stock is valued at $68.90 at 22:22 EST, below its 52-week high of $73.92 and way above its 52-week low of $36.70.

Nelnet, Inc.'s Moving Average

Nelnet, Inc.'s value is below its 50-day moving average of $69.69 and above its 200-day moving average of $62.78.

2. Abbott Laboratories

24.2% sales growth and 10.57% return on equity

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide.

Abbott Laboratories's sales growth this year is expected to be 6.2% and 14% for next year.

Year-on-year quarterly revenue growth grew by 9.6%, now sitting on 32.22B for the twelve trailing months.

Abbott Laboratories's sales growth for the next quarter is 24.2%. The company's growth estimates for the current quarter and the next is 42.1% and 60%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.57%.

Volatility

Abbott Laboratories's last day, last week, and last month's average volatility was a positive 0.84%, a negative 0.08%, and a positive 0.03%, respectively.

Abbott Laboratories's last day, last week, and last month's high and low average amplitude percentage was 1.46%, 2.03%, and 1.69%, respectively.

Abbott Laboratories's Stock Yearly Top and Bottom Value

Abbott Laboratories's stock is valued at $107.79 at 22:22 EST, under its 52-week high of $115.14 and way above its 52-week low of $61.61.

Abbott Laboratories's Moving Average

Abbott Laboratories's worth is below its 50-day moving average of $108.86 and higher than its 200-day moving average of $103.41.

3. Alamos Gold Inc Ordinary Shares

25.3% sales growth and 3.88% return on equity

Alamos Gold Inc., together with its subsidiaries, engages in the acquisition, exploration, development, and extraction of gold deposits in North America.

Alamos Gold Inc Ordinary Shares's sales growth this year is expected to be 18.2% and 10.6% for next year.

Year-on-year quarterly revenue growth grew by 26.3%, now sitting on 707.5M for the twelve trailing months.

Alamos Gold Inc Ordinary Shares's sales growth for the next quarter is 25.3%. The company's growth estimates for the present quarter and the next is 600% and 25%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.88%.

Volatility

Alamos Gold Inc Ordinary Shares's last day, last week, and last month's average volatility was a positive 0.57%, a negative 2.25%, and a positive 0.61%, respectively.

Alamos Gold Inc Ordinary Shares's last day, last week, and last month's high and low average amplitude percentage was 3.01%, 4.66%, and 3.92%, respectively.

Alamos Gold Inc Ordinary Shares's Stock Yearly Top and Bottom Value

Alamos Gold Inc Ordinary Shares's stock is valued at $8.68 at 22:22 EST, way below its 52-week high of $11.58 and way above its 52-week low of $3.34.

Alamos Gold Inc Ordinary Shares's Moving Average

Alamos Gold Inc Ordinary Shares's worth is below its 50-day moving average of $8.86 and under its 200-day moving average of $9.38.

4. Capital Bancorp, Inc.

50.1% sales growth and 15.3% return on equity

Capital Bancorp, Inc. operates as the bank holding company for Capital Bank, N.A. that provides various commercial banking products and services to businesses, not-for-profit associations, and entrepreneurs in the United States.

Capital Bancorp, Inc.'s sales growth this year is expected to be 52.1% and 5.3% for next year.

Year-on-year quarterly revenue growth grew by 63.1%, now sitting on 115.18M for the twelve trailing months.

Capital Bancorp, Inc.'s sales growth for the next quarter is 50.1%. The company's growth estimates for the current quarter and the next is 52.8% and 85.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.3%.

Volatility

Capital Bancorp, Inc.'s last day, last week, and last month's average volatility was 0.29%, 0.37%, and 0.75%, respectively.

Capital Bancorp, Inc.'s last day, last week, and last month's high and low average amplitude percentage was 1.15%, 3.17%, and 3.48%, respectively.

Capital Bancorp, Inc.'s Stock Yearly Top and Bottom Value

Capital Bancorp, Inc.'s stock is valued at $13.93 at 22:22 EST, below its 52-week high of $14.97 and way above its 52-week low of $6.98.

Capital Bancorp, Inc.'s Moving Average

Capital Bancorp, Inc.'s worth is above its 50-day moving average of $12.73 and way higher than its 200-day moving average of $10.98.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge: Late-August 2026 Funding Wave Spans Fintech, Enterprise Agents, and Robotics
A dense cluster of funding rounds landing on 2026-08-28 — from identity/fraud fintech player Socure ($156M plus its acquisition of Fravity) to enterprise AI agent startups (Instinct, Generalist AI, Owner), model infrastructure (Stability AI, Emerald AI), and autonomous logistics/aerospace (Gatik, Regent Craft) — signals investors are rotating aggressively into AI-native companies with demonstrable ROI, especially in financial risk/compliance and back-office automation. Parallel signals (Multiverse Computing's compression benchmarks cutting inference cost/latency, and Arkestro/CloneOps.ai publishing hard savings and labor-displacement figures) suggest the funding is chasing efficiency and measurable economic impact rather than pure model scale.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,980
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,980 facts checked against source5,267 source documents archived
Query this data → isubstrate.com